Literature DB >> 12641873

Clinical epidemiology of cardiac disease in renal transplant recipients.

Claudio Rigatto1.   

Abstract

Cardiovascular disease (CVD) is the major cause of death among renal transplant recipients (RTRs), accounting for 17-50% of deaths. Both cardiomyopathy (congestive heart failure [CHF] and left ventricular hypertrophy [LVH]) and ischemic heart disease (IHD) are important complications of renal transplantation, although the morbid impact of cardiomyopathy has been overlooked until recently. Echocardiographic disorders and clinical CHF occur far more frequently in RTRs than in the general population, suggesting that renal transplantation may be a state of accelerated heart failure. In contrast, the incidence of IHD in RTRs is similar to that in the Framingham cohort. Age, diabetes, and gender remain important markers of risk for both disorders. Smoking, hyperlipidemia, and hypertension appear to be the major reversible risk factors for IHD, while anemia and hypertension are major reversible risk factors for cardiomyopathy. Definitive evidence on optimal intervention is lacking. Clinical trials are needed to define optimum targets for treatment of these risk factors, especially hypertension and anemia.

Entities:  

Mesh:

Year:  2003        PMID: 12641873     DOI: 10.1046/j.1525-139x.2003.16026.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  8 in total

1.  Interferon-γ-mediated allograft rejection exacerbates cardiovascular disease of hyperlipidemic murine transplant recipients.

Authors:  Jing Zhou; Lingfeng Qin; Tai Yi; Rahmat Ali; Qingle Li; Yang Jiao; Guangxin Li; Zuzana Tobiasova; Yan Huang; Jiasheng Zhang; James J Yun; Mehran M Sadeghi; Frank J Giordano; Jordan S Pober; George Tellides
Journal:  Circ Res       Date:  2015-09-23       Impact factor: 17.367

Review 2.  Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients.

Authors:  Lisa M Miller; Manish M Sood; Amy R Sood; Martina Reslerova; Paul Komenda; Claudio Rigatto; Joe Bueti
Journal:  Int Urol Nephrol       Date:  2010-10-20       Impact factor: 2.370

Review 3.  Hypertension in Kidney Transplant Recipients: Where Are We Today?

Authors:  Elif Ari; Francesco Fici; Nicolas Roberto Robles
Journal:  Curr Hypertens Rep       Date:  2021-04-13       Impact factor: 5.369

Review 4.  Benefit-risk assessment of sirolimus in renal transplantation.

Authors:  Dirk R J Kuypers
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Association and prognostic impact of persistent left ventricular hypertrophy after live-donor kidney transplantation: a prospective study.

Authors:  Hussein Attia Sheashaa; Tarek M Abbas; Nabil A Hassan; Khaled M Mahmoud; Amgad E El-Agroudy; Mohamed A Sobh; Mohamed A Ghoneim
Journal:  Clin Exp Nephrol       Date:  2009-10-31       Impact factor: 2.801

6.  Renal transplantation is not associated with regression of left ventricular hypertrophy: a magnetic resonance study.

Authors:  Rajan K Patel; Patrick B Mark; Nicola Johnston; Ellon McGregor; Henry J Dargie; Alan G Jardine
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 8.237

7.  The Reasons of Renal Transplant Recipients' Admission to the Emergency Department; a Case Series Study.

Authors:  Erdal Uysal; Mehmet Dokur; Hasan Bakir; Mehmet Ali Ikidag; Turkay Kirdak; Hatem Kazimoglu
Journal:  Emerg (Tehran)       Date:  2016-11

8.  Effects of Statins on Lipid Profile of Kidney Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Xiu Huang; Yong Jia; Xiaoyu Zhu; Yangyang Zhang; Lili Jiang; Xuejiao Wei; Dan Zhao; Xiaoxia Zhao; Yujun Du
Journal:  Biomed Res Int       Date:  2020-05-02       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.